German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-08 06:58:002019-07-08 06:58:00€30m for Evotec cancer spin-out
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellectis-CAR_T.jpg8001200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-05 06:58:002019-07-05 06:58:00Partnership in pursuit of new antibiotics class
Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.
Outgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2019_Directorate-General_for_Agriculture_and_Rural_Development_in_Brussels.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-07-04 10:28:022024-04-02 16:20:44Bioeconomy: just a way to set up a smarter agriculture?
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellectis-CAR_T.jpg8001200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-04 06:58:002019-07-04 06:58:00Drug puts CAR T activity on hold
Galapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.
https://european-biotechnology.com/wp-content/uploads/2024/04/sscfmtphenotype.png5631000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-07-03 14:55:592019-07-03 14:55:59Biotech company Galapagos improves high-content screening (HCS) in scleroderma with IN Carta Phenoglyphs image analysis
Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Michael Kuhrt/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMichael Kuhrt2019-07-02 09:38:552019-07-02 09:38:55Helena Strigård becomes CEO of Swedenbio
Teckro today announced five significant appointments to its leadership team. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms. To date, Teckro has raised $43 million.
Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.
€30m for Evotec cancer spin-out
Latest NewsGerman biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
Partnership in pursuit of new antibiotics class
Latest NewsA new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
Jens-Peter Marschner joins Zelluna
AppointmentsZelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.
Bioeconomy: just a way to set up a smarter agriculture?
BackgroundOutgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.
Drug puts CAR T activity on hold
Latest NewsGerman researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.
Biotech company Galapagos improves high-content screening (HCS) in scleroderma with IN Carta Phenoglyphs image analysis
Sponsored PublicationsGalapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.
License deal in oncolytic virotherapies
Latest NewsOncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
Helena Strigård becomes CEO of Swedenbio
AppointmentsSwedenbio’s Board has appointed Helena Strigård as the new CEO. Strigård will take up the position on September 1 and replace Jonas Ekstrand,
Teckro Expands Leadership Team
AppointmentsTeckro today announced five significant appointments to its leadership team. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms. To date, Teckro has raised $43 million.
Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal
Latest News